DK2619325T3 - Fremgangsmåde til registrering, kvantificering og kortlæggelse af beskadigelse og/eller reparation af DNA-strenge - Google Patents

Fremgangsmåde til registrering, kvantificering og kortlæggelse af beskadigelse og/eller reparation af DNA-strenge Download PDF

Info

Publication number
DK2619325T3
DK2619325T3 DK11802132.8T DK11802132T DK2619325T3 DK 2619325 T3 DK2619325 T3 DK 2619325T3 DK 11802132 T DK11802132 T DK 11802132T DK 2619325 T3 DK2619325 T3 DK 2619325T3
Authority
DK
Denmark
Prior art keywords
dna
nucleic acid
repair
damage
cells
Prior art date
Application number
DK11802132.8T
Other languages
English (en)
Inventor
Lucia Cinque
Aaron Bensimon
Original Assignee
Genomic Vision
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genomic Vision filed Critical Genomic Vision
Application granted granted Critical
Publication of DK2619325T3 publication Critical patent/DK2619325T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/242—Gold; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6804—Nucleic acid analysis using immunogens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333—Saccharide [e.g., DNA, etc.]

Claims (9)

1. Fremgangsmåde til registrering af tilstedeværelse eller fravær af et repareret parti(er) på en eller flere beskadigede nukleinsyre(r), hvor skaden var frembragt på nukleinsyre i celler, hvilken fremgangsmåde omfatter: (a) behandling af en prøve indeholdende celler i en kultur forud for udtrækning af nukleinsyre(r) fra prøven ved tilsætning af et registrerbart nukleotid eller nukleosid i en periode og under betingelser, som er tilstrækkelige til samvirken med nukleinsyrer, hvori det registrerbare nukleotid eller nukleosid inkorporeres ved et eller flere enzymer, som findes inde i levende celler og er i stand til at fjerne skaden fra nukleinsyren og erstatte den med det registrerbare nukleotid eller nukleosid, (b) udtrækning af en eller flere nukleinsyre(r) fra prøven, og valgfri rensning eller vaskning af den udtrukne nukleinsyreprøve, (c) strækning af den(de) udtrukne nukleinsyre(r), (d) registrering af det registrerbare nukleotid eller nukleosid på den(de) udstrakte nukleinsyre(r), og (e) registrering af tilstedeværelsen af repareret(-de) parti(er) på nukleinsyren, når det registrerbare nukleotid eller nukleosid registreres, og registrering fraværet af et repareret parti på nukleinsyren(-erne), når det registrerbare nukleotid eller nukleosid ikke registreres.
2. Fremgangsmåde ifølge krav 1, hvori den(de) udtrukne nukleinsyre(r) strækkes under brug af Molecular Combing.
3. Fremgangsmåde ifølge krav 1, hvori skaden repareres i levende celler med nu-kleotidfjernelsesreparationssystemet, og hvori stoffet er et kemisk modificeret eller mærket nukleosid, især 5-ethynyl-2'-deoxyuridin, og inkorporeres i beskadigede partier af nukleinsyren(-rne) via ikke-planmæssig DNA-syntese.
4. Fremgangsmåde ifølge ethvert af de foregående krav, som yderligere omfatter: (a) hybridisering af en eller flere sekvensspecifikke sonder svarende til en eller flere specifikke kendte positioner eller regioner på nukleinsyren, og valgfri (b) måling af afstanden eller den rumlige fordeling mellem de hybridiserede sonder og registrerbart nukleotid eller nukleosid svarende til en eller flere reparerede nukleinsyresekvenser.
5. Fremgangsmåde ifølge ethvert af de foregående krav, hvori prøven er en vævsprøve eller blod-, rygmarvs-, ledvæske- eller lymfeprøve.
6. Fremgangsmåde ifølge ethvert af de foregående krav, hvori prøven fremskaffes fra et subjekt, som har kræft, eller som har fået behandling for kræft, eller som har en infektionssygdom, autoimmun sygdom eller inflammatorisk sygdom eller tilstand.
7. Fremgangsmåde til diagnosticering af en sygdom, lidelse eller tilstand i et subjekt, omfattende registrering af repareret(-de) parti(er) i nukleinsyre(r) udtrukket fra en prøve fra dette subjekt ved fremgangsmåden ifølge ethvert af krav 1 til 6.
8. Proces til bestemmelse af virkningen af et testmiddel på en eller flere nukleinsyre^) i en celle, omfattende: - bringe cellen i kontakt med testmidlet i en periode og under betingelser, som er tilstrækkelige til at det beskadiger nukleinsyre(r) i cellen, og - registrere et repareret parti på cellens nukleinsyre(r) ved fremgangsmåden ifølge ethvert af krav 1 til 6, og valgfrit - registrere et eller flere reparerede parti(er) på nukleinsyren(-rne) af i øvrigt identiske celler, som ikke er udsat for testmidlet, og sammenligning af det(de) registrerede reparerede parti(er) med dem, der er i de udsatte celler.
9. Proces ifølge krav 8, hvori testmidlet er en genotoksisk forbindelse eller geno-toksisk ioniserende stråling.
DK11802132.8T 2010-09-24 2011-09-22 Fremgangsmåde til registrering, kvantificering og kortlæggelse af beskadigelse og/eller reparation af DNA-strenge DK2619325T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38635810P 2010-09-24 2010-09-24
PCT/IB2011/002584 WO2012038831A2 (en) 2010-09-24 2011-09-22 A method for detecting, quantifying and mapping damage and/or repair of dna strands

Publications (1)

Publication Number Publication Date
DK2619325T3 true DK2619325T3 (da) 2016-09-05

Family

ID=45870903

Family Applications (1)

Application Number Title Priority Date Filing Date
DK11802132.8T DK2619325T3 (da) 2010-09-24 2011-09-22 Fremgangsmåde til registrering, kvantificering og kortlæggelse af beskadigelse og/eller reparation af DNA-strenge

Country Status (7)

Country Link
US (3) US20120076871A1 (da)
EP (2) EP3078754A1 (da)
CA (1) CA2811716A1 (da)
DK (1) DK2619325T3 (da)
ES (1) ES2587434T3 (da)
IL (2) IL225269A (da)
WO (1) WO2012038831A2 (da)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130115598A1 (en) * 2011-10-13 2013-05-09 Lawrence Loeb Oligonucleotide probe retrieval assay for dna transactions in mammalian cells
CN107922965B (zh) * 2015-04-06 2021-12-07 生捷科技控股公司 基因组的表观遗传修饰的定相方法
WO2018100431A1 (en) 2016-11-29 2018-06-07 Genomic Vision Method for designing a set of polynucleotide sequences for analysis of specific events in a genetic region of interest
EP3676609A4 (en) * 2017-09-01 2021-06-02 Children's Medical Research Institute PROCEDURE FOR EVALUATING TELOMERS
CN111307696A (zh) * 2020-03-19 2020-06-19 浙江星博生物科技股份有限公司 用于检测精子dna碎片率的方法和试剂盒
WO2024020491A1 (en) * 2022-07-20 2024-01-25 The University Of North Carolina At Chapel Hill Methods of treating cancer of the central nervous system comprising 5-ethynyl-2'-deoxyuridine

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2716263B1 (fr) 1994-02-11 1997-01-17 Pasteur Institut Procédé d'alignement de macromolécules par passage d'un ménisque et applications dans un procédé de mise en évidence, séparation et/ou dosage d'une macromolécule dans un échantillon.
AU6252796A (en) 1995-06-07 1996-12-30 Trevigen, Inc. Nucleic acid repair enzyme methods for point mutation detect ion and in vitro mutagenesis
FR2737574B1 (fr) 1995-08-03 1997-10-24 Pasteur Institut Appareillage d'alignement parallele de macromolecules et utilisation
FR2755149B1 (fr) 1996-10-30 1999-01-15 Pasteur Institut Procede de diagnostic de maladies genetiques par peignage moleculaire et coffret de diagnostic
US6248537B1 (en) 1999-05-28 2001-06-19 Institut Pasteur Use of the combing process for the identification of DNA origins of replication
US6789022B2 (en) 2000-04-20 2004-09-07 Brookhaven Science Associates Llc Method for assaying clustered DNA damages
WO2002101095A1 (en) * 2001-06-08 2002-12-19 U.S. Genomics, Inc. Methods and products for analyzing nucleic acids using nick translation
EP1402071A4 (en) * 2001-06-08 2005-12-14 Us Genomics Inc METHOD AND PRODUCTS FOR THE ANALYSIS OF NUCLEIC ACIDS BASED ON THE METHYLATION STATUS
SG187992A1 (en) 2001-07-25 2013-03-28 Univ Princeton Nanochannel arrays and their preparation and use for high throughput macromolecular analysis
US7282330B2 (en) * 2002-05-28 2007-10-16 U.S. Genomics, Inc. Methods and apparati using single polymer analysis
JP2004049182A (ja) * 2002-07-24 2004-02-19 Bio Oriented Technol Res Advancement Inst Ｄｎａ脱塩基部位の検出方法
US7985542B2 (en) * 2006-09-07 2011-07-26 Institut Pasteur Genomic morse code
EP2604344A3 (en) 2007-03-28 2014-07-16 BioNano Genomics, Inc. Methods of macromolecular analysis using nanochannel arrays
US20100137154A1 (en) * 2008-12-01 2010-06-03 Ach Robert A Genome analysis using a methyltransferase

Also Published As

Publication number Publication date
IL225269A (en) 2016-10-31
WO2012038831A3 (en) 2012-05-24
US20140220160A1 (en) 2014-08-07
EP2619325A2 (en) 2013-07-31
IL225269A0 (en) 2013-06-27
CA2811716A1 (en) 2012-03-29
US20170029876A1 (en) 2017-02-02
WO2012038831A2 (en) 2012-03-29
EP2619325B1 (en) 2016-06-01
IL248334A0 (en) 2016-11-30
ES2587434T3 (es) 2016-10-24
US20120076871A1 (en) 2012-03-29
EP3078754A1 (en) 2016-10-12

Similar Documents

Publication Publication Date Title
US20170029876A1 (en) Method for detecting, quantifying and mapping damage and/or repair of dna strands
JP6578205B2 (ja) 癌におけるマイクロサテライト不安定性を検出しｄｎａ塩基除去修復経路の阻害による合成致死性を決定するための新規なマーカー
Van Overveld et al. Variable hypomethylation of D4Z4 in facioscapulohumeral muscular dystrophy
CA2860312C (en) Methods and materials for assessing loss of heterozygosity
AU2006326385B2 (en) Use of ROMA for characterizing genomic rearrangements
Decordier et al. Phenotyping for DNA repair capacity
Brenerman et al. Base excision repair capacity in informing healthspan
Tian et al. A robust genomic signature for the detection of colorectal cancer patients with microsatellite instability phenotype and high mutation frequency
WO2015171457A1 (en) Methods of identifying biomarkers associated with or causative of the progression of disease, in particular for use in prognosticating primary open angle glaucoma
Furst et al. DNA electrochemistry shows DNMT1 methyltransferase hyperactivity in colorectal tumors
Paulet et al. Cracking the homologous recombination deficiency code: how to identify responders to PARP inhibitors
Rana Crime investigation through DNA methylation analysis: methods and applications in forensics
Millau et al. A microarray to measure repair of damaged plasmids by cell lysates
US20130177921A1 (en) Detection of Damage to DNA
Parra et al. Single cell multi-omics analysis of chromothriptic medulloblastoma highlights genomic and transcriptomic consequences of genome instability
Türke et al. Loss of heterozygosity in FANCG, FANCF and BRIP1 from head and neck squamous cell carcinoma of the oral cavity
KR20170127774A (ko) 유전자의 결실을 이용한 유방암 환자의 예후 예측 방법
Niazi et al. DNA repair gene polymorphisms and chromosomal aberrations in healthy, nonsmoking population
JP5116938B2 (ja) 哺乳動物由来の検体の癌化度を評価する方法
Li et al. Myometrial Oxidative Stress Drives MED12 Mutations for Leiomyoma development
CA3181090A1 (en) Methods for predicting treatment response in cancers
Hannaway The investigation of circulating biomarkers and potential mechanisms of resistance in the ATR/CHK1 signalling pathway in response to CHK1 inhibitor therapy
WO2023084104A1 (en) Methods for detecting and predicting breast cancer
Alvarez Epigenetic regulation of DNA repair mediated by the histone methyltransferase DOT1L
Milbury Genome instability in multiple myeloma-associated DIS3 exonuclease domain mutants